Two Sigma Advisers
AVBP icon

Two Sigma Advisers’s ArriVent BioPharma AVBP Stock Holding History

Two Sigma Advisers’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-37,100
Closed -$746K – 2225
2025
Q4 		$746K Sell
37,100
-6,700
-15% -$139K ﹤0.01% 1627
2025
Q3 		$808K Buy
43,800
+10,500
+32% +$206K ﹤0.01% 1567
2025
Q2 		$725K Buy
33,300
+15,300
+85% +$318K ﹤0.01% 1587
2025
Q1 		$333K Buy
+18,000
New +$441K ﹤0.01% 1951

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Advisers's AVBP Position: Q1 2026 in Review

Two Sigma Advisers sold out of ArriVent BioPharma (AVBP) in Q1 2026, closing a stake of 37,100 shares — an estimated $746K sold.

Two Sigma Advisers first reported a position in AVBP in Q1 2025 and held it in 4 quarters. The position peaked at $808K in Q3 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Two Sigma Advisers reported no remaining ArriVent BioPharma position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 37,100 ArriVent BioPharma shares in Q1 2026, an estimated $746K.
  • Two Sigma Advisers first reported a position in ArriVent BioPharma in Q1 2025 and held it in 4 quarters.
  • Two Sigma Advisers's ArriVent BioPharma position peaked at $808K in Q3 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.